Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 253

1.

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.

Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suciu S.

JAMA Oncol. 2020 Jan 2. doi: 10.1001/jamaoncol.2019.5570. [Epub ahead of print]

PMID:
31895407
2.

Primary Cilia Signaling Promotes Axonal Tract Development and Is Disrupted in Joubert Syndrome-Related Disorders Models.

Guo J, Otis JM, Suciu SK, Catalano C, Xing L, Constable S, Wachten D, Gupton S, Lee J, Lee A, Blackley KH, Ptacek T, Simon JM, Schurmans S, Stuber GD, Caspary T, Anton ES.

Dev Cell. 2019 Dec 16;51(6):759-774.e5. doi: 10.1016/j.devcel.2019.11.005.

3.

Long-term outcome evaluation of medium/high risk acute lymphoblastic leukaemia children treated with or without cranial radiotherapy in the EORTC 58832 randomized study.

Piette C, Suciu S, Bertrand Y, Uyttebroeck A, Vandecruys E, Plat G, Paillard C, Pluchart C, Sirvent N, Maurus R, Poirée M, Simon P, Ferster A, Hoyoux C, Mazingue F, Paulus R, Freycon C, Thomas C, Philippet P, Gilotay C, van der Werff Ten Bosch J, Rohrlich PS, Benoit Y.

Br J Haematol. 2019 Dec 13. doi: 10.1111/bjh.16337. [Epub ahead of print]

PMID:
31837008
4.

Correction to: Abstracts : 31st European Congress of Pathology.

Nataras BR, Dema A, Lazureanu CD, Herman D, Taban S, Cornianu M, Szilagyi D, Muresan A, Costi S, Uglai I, Suciu SC, Anderco D, Iacob M.

Virchows Arch. 2019 Nov 6. doi: 10.1007/s00428-019-02690-x. [Epub ahead of print]

PMID:
31691848
5.

A Novel Thiazolyl Schiff Base: Antibacterial and Antifungal Effects and In Vitro Oxidative Stress Modulation on Human Endothelial Cells.

Login CC, Bâldea I, Tiperciuc B, Benedec D, Vodnar DC, Decea N, Suciu Ş.

Oxid Med Cell Longev. 2019 Oct 10;2019:1607903. doi: 10.1155/2019/1607903. eCollection 2019.

6.

Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas.

Verver D, Poirier-Colame V, Tomasic G, Cherif-Rebai K, Grunhagen DJ, Verhoef C, Suciu S, Robert C, Zitvogel L, Eggermont AMM.

Oncoimmunology. 2019 Sep 6;8(11):e1660121. doi: 10.1080/2162402X.2019.1660121. eCollection 2019.

PMID:
31646109
7.

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.

Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Hosein F, de Pril V, Kicinski M, Suciu S, Testori A.

Eur J Cancer. 2019 Sep;119:1-10. doi: 10.1016/j.ejca.2019.07.001. Epub 2019 Aug 7.

PMID:
31400634
8.

Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia.

Galimberti S, Devidas M, Lucenti A, Cazzaniga G, Möricke A, Bartram CR, Mann G, Carroll W, Winick N, Borowitz M, Wood B, Basso G, Conter V, Zimmermann M, Suciu S, Biondi A, Schrappe M, Hunger SP, Valsecchi MG.

JNCI Cancer Spectr. 2018 Dec 19;2(4):pky069. doi: 10.1093/jncics/pky069. eCollection 2018 Oct.

9.

Liposomal Curcumin Enhances the Effect of Naproxen in a Rat Model of Migraine.

Bulboacă AE, Bolboacă SD, Bulboacă AC, Porfire AS, Tefas LR, Suciu ȘM, Dogaru G, Stănescu IC.

Med Sci Monit. 2019 Jul 9;25:5087-5097. doi: 10.12659/MSM.915607.

10.

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suciu S, Robert C.

Eur J Cancer. 2019 Jul;116:148-157. doi: 10.1016/j.ejca.2019.05.020. Epub 2019 Jun 11.

PMID:
31200321
11.

Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.

Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, Keilholz U, Zimmer L, Patel SP, Piperno-Neumann S, Piulats J, Kivelä TT, Pfoehler C, Bhatia S, Huppert P, Van Iersel LBJ, De Vries IJM, Penel N, Vogl T, Cheng T, Fiorentini G, Mouriaux F, Tarhini A, Patel PM, Carvajal R, Joshua AM.

Ann Oncol. 2019 Aug 1;30(8):1370-1380. doi: 10.1093/annonc/mdz176.

PMID:
31150059
12.

Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL).

Hofmans M, Suciu S, Ferster A, Van Vlierberghe P, Mazingue F, Sirvent N, Costa V, Yakouben K, Paillard C, Uyttebroeck A, Plantaz D, Plat G, Simon P, Millot F, Poirée M, van der Werff Ten Bosch J, Piette C, Minckes O, Rohrlich P, Girard S, Cavé H, Bertrand Y, De Moerloose B.

Br J Haematol. 2019 Sep;186(5):741-753. doi: 10.1111/bjh.15983. Epub 2019 May 24.

13.

Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients.

Baron F, Efficace F, Cannella L, Willemze R, Vignetti M, Muus P, Marie JP, Ferrero D, Fazi P, La Sala E, Bourhis JH, Fabbiano F, Bosi A, Sborgia M, Martinelli G, Wittnebel S, Trisolini S, Petti MC, Halkes CJM, van der Velden WJFM, de Witte T, Amadori S, Zittoun RA, Suciu S.

Haematologica. 2020 Jan;105(1):e13-e16. doi: 10.3324/haematol.2019.221333. Epub 2019 May 16. No abstract available.

14.

Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma.

Eggermont A, Suciu S, Kicinski M.

N Engl J Med. 2019 Apr 4;380(14):1374-1376. doi: 10.1056/NEJMc1902228. No abstract available.

PMID:
30943345
15.

10-day vs 5-day decitabine: equivalence cannot be concluded.

Huls G, Suciu S, Wijermans P, Kicinski M, Lübbert M.

Lancet Haematol. 2019 Apr;6(4):e177. doi: 10.1016/S2352-3026(19)30024-9. No abstract available.

PMID:
30926076
16.

Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype.

Baron F, Stevens-Kroef M, Kicinski M, Meloni G, Muus P, Marie JP, Halkes CJM, Thomas X, Vrhovac R, Albano F, Lefrère F Sr, Sica S, Mancini M, Venditti A, Hagemeijer A, Jansen JH, Amadori S, de Witte T, Willemze R, Suciu S.

Haematologica. 2019 Jun;104(6):1168-1175. doi: 10.3324/haematol.2018.204826. Epub 2018 Dec 6.

17.

The role of PDGF-B/PDGFR-BETA axis in the normal development and carcinogenesis of the breast.

Jitariu AA, Raica M, Cîmpean AM, Suciu SC.

Crit Rev Oncol Hematol. 2018 Nov;131:46-52. doi: 10.1016/j.critrevonc.2018.08.002. Epub 2018 Aug 28. Review.

PMID:
30293705
18.

Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome.

Stomper J, Ihorst G, Suciu S, Sander PN, Becker H, Wijermans PW, Plass C, Weichenhan D, Bissé E, Claus R, Lübbert M.

Haematologica. 2019 Jan;104(1):59-69. doi: 10.3324/haematol.2017.187278. Epub 2018 Aug 31.

19.

Adjuvant Pembrolizumab in Resected Stage III Melanoma.

Eggermont AMM, Robert C, Suciu S.

N Engl J Med. 2018 Aug 9;379(6):593-595. doi: 10.1056/NEJMc1807505. No abstract available.

PMID:
30089063
20.

Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.

Baron F, Stevens-Kroef M, Kicinski M, Meloni G, Muus P, Marie JP, Halkes CJM, Thomas X, Vrhovac R, Specchia G, Lefrere F Sr, Sica S, Mancini M, Venditti A, Hagemeijer A, Becker H, Jansen JH, Amadori S, de Witte T, Willemze R, Suciu S.

Ann Hematol. 2018 Oct;97(10):1785-1795. doi: 10.1007/s00277-018-3396-4. Epub 2018 Jun 20.

21.

Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial.

Michels J, Becker N, Suciu S, Kaiser I, Benner A, Kosaloglu-Yalcin Z, Agoussi S, Halama N, Pawlita M, Waterboer T, Eichmüller SB, Jäger D, Eggermont AMM, Zörnig I.

Oncoimmunology. 2018 Feb 12;7(6):e1428157. doi: 10.1080/2162402X.2018.1428157. eCollection 2018.

22.

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C.

N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.

23.

Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies.

Testori AA, Suciu S, van Akkooi ACJ, Suppa M, Eggermont AMM, de Vries E, Joosse A; European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group.

Melanoma Res. 2018 Jun;28(3):222-229. doi: 10.1097/CMR.0000000000000433.

PMID:
29432281
24.

Attitudes toward mentally ill patients: a comparison between Romanian and international medical students.

Popescu CA, Buzoianu AD, Suciu SM, Armean SM.

Clujul Med. 2017;90(4):401-406. doi: 10.15386/cjmed-776. Epub 2017 Oct 20.

25.

Multimarker Assessment of Diastolic Dysfunction in Metabolic Syndrome Patients.

Mocan M, Anton F, Suciu Ș, Răhăian R, Blaga SN, Fărcaș AD.

Metab Syndr Relat Disord. 2017 Dec;15(10):507-514. doi: 10.1089/met.2017.0060. Epub 2017 Nov 3.

PMID:
29099655
26.

Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials.

Piette C, Suciu S, Clappier E, Bertrand Y, Drunat S, Girard S, Yakouben K, Plat G, Dastugue N, Mazingue F, Grardel N, van Roy N, Uyttebroeck A, Costa V, Minckes O, Sirvent N, Simon P, Lutz P, Ferster A, Pluchart C, Poirée M, Freycon C, Dresse MF, Millot F, Chantrain C, van der Werff Ten Bosch J, Norga K, Gilotay C, Rohrlich PS, Benoit Y, Cavé H.

Leukemia. 2018 Jan;32(1):244-248. doi: 10.1038/leu.2017.289. Epub 2017 Sep 19. No abstract available.

27.

Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.

Suciu S, Eggermont AMM, Lorigan P, Kirkwood JM, Markovic SN, Garbe C, Cameron D, Kotapati S, Chen TT, Wheatley K, Ives N, de Schaetzen G, Efendi A, Buyse M.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx133. Review.

PMID:
28922786
28.

Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.

Mondelaers V, Suciu S, De Moerloose B, Ferster A, Mazingue F, Plat G, Yakouben K, Uyttebroeck A, Lutz P, Costa V, Sirvent N, Plouvier E, Munzer M, Poirée M, Minckes O, Millot F, Plantaz D, Maes P, Hoyoux C, Cavé H, Rohrlich P, Bertrand Y, Benoit Y; Children–s Leukemia Group (CLG) of the European Organization for Research and Treatment of Cancer (EORTC).

Haematologica. 2017 Oct;102(10):1727-1738. doi: 10.3324/haematol.2017.165845. Epub 2017 Jul 27.

29.

Chondroprotective effects of pulsed shortwave therapy in rabbits with experimental osteoarthritis.

Ungur RA, Florea A, Tăbăran AF, Scurtu IC, Onac I, Borda IM, Irsay L, Ciortea VM, Dronca E, Zdrenghea MT, Suciu ŞM.

Rom J Morphol Embryol. 2017;58(2):465-472.

30.

Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.

Ives NJ, Suciu S, Eggermont AMM, Kirkwood J, Lorigan P, Markovic SN, Garbe C, Wheatley K; International Melanoma Meta-Analysis Collaborative Group (IMMCG).

Eur J Cancer. 2017 Sep;82:171-183. doi: 10.1016/j.ejca.2017.06.006. Epub 2017 Jul 7. Review.

PMID:
28692949
31.

Corrigendum to "Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy" [Eur J Cancer 67 (2016) 38-45].

Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, Sacré L, Baurain JF, Thomas L, Beutels P, Speybroeck N.

Eur J Cancer. 2017 Sep;82:247. doi: 10.1016/j.ejca.2017.06.001. Epub 2017 Jun 26. No abstract available.

PMID:
28662904
32.

Carbon nanotubes as anti-bacterial agents.

Mocan T, Matea CT, Pop T, Mosteanu O, Buzoianu AD, Suciu S, Puia C, Zdrehus C, Iancu C, Mocan L.

Cell Mol Life Sci. 2017 Oct;74(19):3467-3479. doi: 10.1007/s00018-017-2532-y. Epub 2017 May 23. Review.

PMID:
28536787
33.

Real case of primitive embryonal duodenal carcinoma in a young man.

Barbieux J, Memeo R, De Blasi V, Suciu S, Faucher V, Averous G, Roy C, Marescaux J, Mutter D, Pessaux P.

World J Gastroenterol. 2017 Jan 28;23(4):730-734. doi: 10.3748/wjg.v23.i4.730.

34.

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.

Coens C, Suciu S, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bottomley A, Kotapati S, de Pril V, Testori A, Eggermont AMM.

Lancet Oncol. 2017 Mar;18(3):393-403. doi: 10.1016/S1470-2045(17)30015-3. Epub 2017 Feb 3.

35.

Ipilimumab Adjuvant Therapy in Melanoma.

Eggermont AMM, Suciu S, Testori A.

N Engl J Med. 2017 Jan 26;376(4):399. doi: 10.1056/NEJMc1615564. No abstract available.

PMID:
28121506
36.

Physician migration at its roots: a study on the emigration preferences and plans among medical students in Romania.

Suciu ŞM, Popescu CA, Ciumageanu MD, Buzoianu AD.

Hum Resour Health. 2017 Jan 19;15(1):6. doi: 10.1186/s12960-017-0181-8.

37.

New pharmacological strategies in rheumatic diseases.

Schiotis RE, Buzoianu AD, Mureșanu DF, Suciu S.

J Med Life. 2016 Jul-Sep;9(3):227-234. Review.

38.

Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).

Lübbert M, Ihorst G, Sander PN, Bogatyreva L, Becker H, Wijermans PW, Suciu S, Bissé E, Claus R.

Br J Haematol. 2017 Feb;176(4):609-617. doi: 10.1111/bjh.14463. Epub 2016 Dec 1.

PMID:
27905102
39.

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial.

Selleslag D, Suciu S, Meloni G, Muus P, Halkes CJ, Venditti A, Ramadan SM, Pruijt H, Meert L, Vignetti M, Marie JP, Wittnebel S, de Witte T, Amadori S, Willemze R, Baron F.

Haematologica. 2017 Feb;102(2):e47-e51. doi: 10.3324/haematol.2016.153130. Epub 2016 Oct 27. No abstract available.

40.

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bastholt L, Mortier L, Thomas L, Tahir S, Hauschild A, Hassel JC, Hodi FS, Taitt C, de Pril V, de Schaetzen G, Suciu S, Testori A.

N Engl J Med. 2016 Nov 10;375(19):1845-1855. Epub 2016 Oct 7. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

41.

Arl13b regulates Shh signaling from both inside and outside the cilium.

Mariani LE, Bijlsma MF, Ivanova AA, Suciu SK, Kahn RA, Caspary T.

Mol Biol Cell. 2016 Sep 28. pii: mbc.E16-03-0189. [Epub ahead of print] Erratum in: Mol Biol Cell. 2017 Apr 1;28(7):996. Ivanova, Anna I [corrected to Ivanova, Anna A].

42.

Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy.

Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, Sacré L, Baurain JF, Thomas L, Beutels P, Speybroeck N.

Eur J Cancer. 2016 Nov;67:38-45. doi: 10.1016/j.ejca.2016.07.020. Epub 2016 Sep 2. Erratum in: Eur J Cancer. 2017 Sep;82:247.

PMID:
27592070
43.

Credibility judgments in web page design - a brief review.

Selejan O, Muresanu DF, Popa L, Muresanu-Oloeriu I, Iudean D, Buzoianu A, Suciu S.

J Med Life. 2016 Apr-Jun;9(2):115-9. Review.

44.

Gait analysis and functional outcomes after twelve-week rehabilitation in patients with surgically treated ankle fractures.

Suciu O, Onofrei RR, Totorean AD, Suciu SC, Amaricai EC.

Gait Posture. 2016 Sep;49:184-189. doi: 10.1016/j.gaitpost.2016.07.006. Epub 2016 Jul 7.

PMID:
27434488
45.

Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.

Krogh M, Christensen I, Bouwhuis M, Johansen JS, Nørgaard P, Schmidt H, Hansson J, Suciu S, Eggermont AM, Bastholt L; Nordic Melanoma Group and EORTC Melanoma Group.

Melanoma Res. 2016 Aug;26(4):367-76. doi: 10.1097/CMR.0000000000000237.

PMID:
27076041
46.

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.

Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, Annino L, Venditti A, Voso MT, Mazzone C, Magro D, De Fabritiis P, Muus P, Alimena G, Mancini M, Hagemeijer A, Paoloni F, Vignetti M, Fazi P, Meert L, Ramadan SM, Willemze R, de Witte T, Baron F.

J Clin Oncol. 2016 Mar 20;34(9):972-9. doi: 10.1200/JCO.2015.64.0060. Epub 2016 Jan 25.

47.

Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.

Eggermont AM, Suciu S, Rutkowski P, Kruit WH, Punt CJ, Dummer R, Salès F, Keilholz U, de Schaetzen G, Testori A; EORTC Melanoma Group.

Eur J Cancer. 2016 Mar;55:111-21. doi: 10.1016/j.ejca.2015.11.014. Epub 2016 Jan 17.

PMID:
26790144
48.

Melanoma burden by melanoma stage: Assessment through a disease transition model.

Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, Francart J, Calay F, Haagsma JA, Baurain JF, Thomas L, Beutels P, Speybroeck N.

Eur J Cancer. 2016 Jan;53:33-41. doi: 10.1016/j.ejca.2015.09.016. Epub 2015 Dec 13.

PMID:
26693897
49.

Comparative animal study of the antinociceptive efficacy of lamotrigine and gabapentin for the management of pain.

Szabo AZ, Bocsan IC, Suciu S, Buzoianu AD.

Acta Physiol Hung. 2015 Dec;102(4):363-71. doi: 10.1556/036.102.2015.4.3.

PMID:
26690028
50.

Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.

Lübbert M, Suciu S, Hagemeijer A, Rüter B, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Schaefer HE, Bogatyreva L, Aul C, de Witte T, Ganser A, Becker H, Huls G, van der Helm L, Vellenga E, Baron F, Marie JP, Wijermans PW; EORTC Leukemia Group and the German MDS Study Group.

Ann Hematol. 2016 Jan;95(2):191-9. doi: 10.1007/s00277-015-2547-0. Epub 2015 Nov 23.

Supplemental Content

Support Center